Ontology highlight
ABSTRACT: Introduction
Molecular diagnostics of newly diagnosed patients with metastatic NSCLC (mNSCLC) with limited tissue samples often face several obstacles in routine practice using next-generation sequencing (NGS), mainly owing to insufficient tissue or DNA; thus, how to effectively identify the molecular profiling of these cases to accurately guide targeted therapy remains elusive. We evaluated whether an optimized workflow with the combined use of multiple technologies could be helpful.Methods
Tissue NGS was used as the frontline method. Amplification refractory mutation system polymerase chain reaction, immunohistochemistry, fluorescence in situ hybridization, and plasma NGS were used as supplements.Results
Among 208 mNSCLC cases with limited tissue (cohort 1), molec
SUBMITTER: Li W
PROVIDER: S-EPMC8474491 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature